Therapeutic monitoring of vancomycin for serious methicillin-resistantStaphylococcus aureusinfections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
- 19 March 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 77 (11), 835-864
- https://doi.org/10.1093/ajhp/zxaa036
Abstract
The first consensus guideline for therapeutic monitoring of vancomycin in adult patients was published in 2009. A committee representing 3 organizations (the American Society for Health-System Pharmacists [ASHP], Infectious Diseases Society of America [IDSA], and Society for Infectious Diseases Pharmacists [SIDP]) searched and reviewed all relevant peer-reviewed data on vancomycin as it related to in vitro and in vivo pharmacokinetic and pharmacodynamic (PK/PD) characteristics, including information on clinical efficacy, toxicity, and vancomycin resistance in relation to serum drug concentration and monitoring. The data were summarized, and specific dosing and monitoring recommendations were made. The primary recommendations consisted of eliminating routine monitoring of serum peak concentrations, emphasizing a ratio of area under the curve over 24 hours to minimum inhibitory concentration (AUC/MIC) of ≥400 as the primary PK/PD predictor of vancomycin activity, and promoting serum trough concentrations of 15 to 20 mg/L as a surrogate marker for the optimal vancomycin AUC/MIC if the MIC was ≤1 mg/L in patients with normal renal function. The guideline also recommended, albeit with limited data support, that actual body weight be used to determine the vancomycin dosage and loading doses for severe infections in patients who were seriously ill.1Keywords
This publication has 192 references indexed in Scilit:
- Effect of Continuous Venovenous Hemofiltration Dose on Achievement of Adequate Vancomycin Trough ConcentrationsAntimicrobial Agents and Chemotherapy, 2012
- Vancomycin AUC 24 /MIC Ratio in Patients with Complicated Bacteremia and Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus and Its Association with Attributable Mortality during HospitalizationAntimicrobial Agents and Chemotherapy, 2012
- Applying New Diagnostic Criteria for Acute Kidney Injury To Facilitate Early Identification of Nephrotoxicity in Vancomycin-Treated PatientsAntimicrobial Agents and Chemotherapy, 2011
- Determination of Vancomycin and Daptomycin MICs by Different Testing Methods for Methicillin-Resistant Staphylococcus aureusJournal of Clinical Microbiology, 2011
- Vancomycin Dosing in Critically Ill Patients: Robust Methods for Improved Continuous-Infusion RegimensAntimicrobial Agents and Chemotherapy, 2011
- Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guidelineBritish Journal of Clinical Pharmacology, 2010
- Prospectively Validated Dosing Nomograms for Maximizing the Pharmacodynamics of Vancomycin Administered by Continuous Infusion in Critically Ill PatientsAntimicrobial Agents and Chemotherapy, 2009
- Current Recommended Dosing of Vancomycin for Children With Invasive Methicillin-Resistant Staphylococcus aureus Infections Is InadequateThe Pediatric Infectious Disease Journal, 2009
- Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with VancomycinAntimicrobial Agents and Chemotherapy, 2008
- Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of NephrotoxicityAntimicrobial Agents and Chemotherapy, 2008